Daniel Vitt, Immunic Therapeutics CEO
Immunic touts positive data in maintenance phase of failed PhII trial, pulls back on another asset
A New York biotech is now saying it has positive maintenance data from a Phase II trial, more than 10 months after reporting the original …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
